Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v1-EN
Language French English
Date Updated 2025-04-03 2025-04-03
Drug Identification Number 02482746 02482746
Brand name MORPHINE SULFATE INJECTION, USP MORPHINE SULFATE INJECTION, USP
Common or Proper name MORPHINE SULFATE INJECTION, USP MORPHINE SULFATE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients MORPHINE SULFATE MORPHINE SULFATE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 1mL 1mL
ATC code N02AA N02AA
ATC description OPIOIDS OPIOIDS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2025-04-25 2025-04-25
Estimated end date 2025-06-18 2025-06-18
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Morphine Sulfate Injection, USP 10 mg / mL SD Vial 1 mL effective April 25, 2025, until June 18, 2025. Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Morphine Sulfate Injection, USP 10 mg / mL SD Vial 1 mL effective April 25, 2025, until June 18, 2025.
Health Canada comments